The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2024 | The effect of lymphodepleting agents on rate and severity of toxicities following CAR-T infusion
In this video, Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, outlines the three major toxicities associated with CAR T-cell therapy and comments on how the choice of agents during lymphodepletion may influence the rates and severity of these toxicities. Fludarabine/cyclophosphamide (Flu/Cy) lymphodepletion increases in efficacy as the dose of the chemotherapy is increased; however, this also leads to more significant toxicity. Increasing evidence has shown that lymphodepletion using bendamustine is equally efficacious, with lower levels of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and long-term cytopenias (as a result of faster neutrophil recovery). This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
